Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred R Hirsch

Showing results (101-110 of 407) with videos related to

Pageof 41
Sort By:
Lung Cancer (Amsterdam, Netherlands)|April 24, 2021
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysisKohei Horiuchi, Takashi Sato, Toshiki Kuno, et al.
Clinical Lung Cancer|May 19, 2023
Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?Noy Meshulami, Sooyun Tavolacci, Diego de Miguel-Perez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2010
Biomarkers are here to stay for clinical research and standard carePaul A Bunn, Fred R Hirsch, Robert C Doebele, et al.
Translational Lung Cancer Research|March 15, 2021
The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative reviewYu Liu, Peixin Chen, Hao Wang, et al.
Cancer Medicine|May 2, 2022
Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United StatesRajwanth Veluswamy, Fred R Hirsch, Emanuela Taioli, et al.
The Journal of International Medical Research|October 12, 2018
Risk factors for nicotine dependence in Chinese patients with lung cancerFen Gu, Yayi He, Yanjun Mao, et al.
Clinical Breast Cancer|June 12, 2002
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell linesFred R Hirsch, Barbara Helfrich, Wilbur A Franklin, et al.
Vaccines|May 27, 2023
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short ReviewAnanda M Rodilla, Sooyun Tavolacci, Jazz Cagan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2015
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung CancerDenis Soulières, Fred R Hirsch, Frances A Shepherd, et al.
The Oncologist|October 6, 2025
Antibody drugs conjugates in non-small cell lung cancer: current status and challengesArjun Syal, May-Lucie Meyer, Kenneth Angelino, et al.
Pageof 41

Showing results (101-110 of 407) with videos related to

Sort By:
Pageof 41
Lung Cancer (Amsterdam, Netherlands)|April 24, 2021
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysisKohei Horiuchi, Takashi Sato, Toshiki Kuno, et al.
Clinical Lung Cancer|May 19, 2023
Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?Noy Meshulami, Sooyun Tavolacci, Diego de Miguel-Perez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2010
Biomarkers are here to stay for clinical research and standard carePaul A Bunn, Fred R Hirsch, Robert C Doebele, et al.
Translational Lung Cancer Research|March 15, 2021
The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative reviewYu Liu, Peixin Chen, Hao Wang, et al.
Cancer Medicine|May 2, 2022
Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United StatesRajwanth Veluswamy, Fred R Hirsch, Emanuela Taioli, et al.
The Journal of International Medical Research|October 12, 2018
Risk factors for nicotine dependence in Chinese patients with lung cancerFen Gu, Yayi He, Yanjun Mao, et al.
Clinical Breast Cancer|June 12, 2002
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell linesFred R Hirsch, Barbara Helfrich, Wilbur A Franklin, et al.
Vaccines|May 27, 2023
Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short ReviewAnanda M Rodilla, Sooyun Tavolacci, Jazz Cagan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2015
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung CancerDenis Soulières, Fred R Hirsch, Frances A Shepherd, et al.
The Oncologist|October 6, 2025
Antibody drugs conjugates in non-small cell lung cancer: current status and challengesArjun Syal, May-Lucie Meyer, Kenneth Angelino, et al.
Pageof 41